ICYMI, the largest three pharmaceutical wholesalers—Cardinal Health, Cencora, and McKesson—are using vertical integration to build significant market positions in businesses beyond drug distribution.
In the video clip below, I review the vertical integration status of the largest three pharmaceutical wholesalers, illustrated in the chart below.
[Click to Enlarge]
I also:
Explain how wholesalers have strengthened their position in buy-and-bill channels for provider-administered drugs through vertical integration with their downstream customers.
Discuss how and why private equity roll-up activity has provided wholesalers with strategic opportunities to acquire ownership stakes in practice management companies.
Outline the market access implications for provider-administered biosimilars in the buy-and-bill market.
Informa Connect's Access USA March 18-20, 2025, Pre-Event Workshops on March 17
Drug Channels readers save 10%* on their registration with code 25AUSA10
Three events. One roof. The future of patient access.
There’s a lot to discuss, and Access USA is ready to deliver: policy updates, PBM reform, commercialization strategies and more!
Meet with hundreds of key stakeholders across the access landscape and benchmark with, learn from and network with leaders paving the way in patient access. Choose your preferred event and prepare to walk away inspired and armed with the knowledge necessary to drive change forward.
Which event is for you?
PAP 2025 Download Agenda This forum gathers experts to share strategies for program optimization, navigate policy change and adapt to market dynamics to transform patient outcomes and maximize medication access. Benchmark your PAP program against leaders in industry and explore best practices to empower patients, champion affordability and accelerate access.
Hub and Specialty Pharmacy Models Download Agenda As the patient services landscape undergoes massive transformation, unite with industry to talk hub optimization and sustainability. In a time where flexibility in your hub program is a must, ensure you have all the tools to remain agile in this fluctuating landscape. This event is your insider playbook to driving efficiency in hub operations for improved access and adherence.
Rare Disease Summit Download Agenda While the industry has seen heightened focus surrounding rare drug development, we’ve only scratched the surface. Connect with key stakeholders to drive therapeutic progress, propel commercial strategies and inspire impactful advocacy. Generate solution-focused approaches surrounding access, commercialization, funding, partnering and more, as you unify in areas of unmet medical need at this inspiring summit.
What attendees are saying:
"Excellent conference! Content is always up-to-date and relevant… I attend yearly and always learn about topics impacting our industry."
"Valuable insights related to access and coverage relative to the impact of government policies and regulations… a window into the critical factors that impact manufacturers, supporting vendors and patient advocacy organizations."
"This event was exactly what I needed... the ability to connect with others on a more granular level guarantees that you will have some much-needed takeaways to share as well as networking with industry leaders!"
*Cannot be combined with other offers or used toward a current registration. Other restrictions may apply.
The content of Sponsored Posts does not necessarily reflect the views of HMP Omnimedia, LLC, Drug Channels Institute, its parent company, or any of its employees. To find out how you can publish an event post on Drug Channels, please contact Paula Fein(paula@DrugChannels.net).
